DiscoverJNM Podcast
JNM Podcast
Claim Ownership

JNM Podcast

Author: JNM

Subscribed: 2Played: 8
Share

Description

Podcast of The Journal of Nuclear Medicine (JNM)—a leading medical imaging journal self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI). In JNM Podcast, our esteemed editors speak with experts in the field to discuss emerging technologies and rapidly changing issues in practice and research.

JNM: https://jnm.snmjournals.org
SNMMI: http://www.snmmi.org

6 Episodes
Reverse
Join us for episode 6 of the JNM podcast. Moderator Ken Herrmann, MD is joined by Simron Singh, MD and Lisa Bodei, MD, PhD to discuss NETTER-2. NETTER-2 was the first trial to examine radioligand therapy as a first-line therapy for cancers, as opposed to waiting until later stages. Our panelists discuss the results of this trial and its implications for patients.Thank you to SOFIE Biosciences for sponsoring this episode. https://sofie.com/
Radioligand therapy (RLT) targets cancer cells with radiation while minimizing impact on surrounding healthy tissue. In this episode of JNM Podcast, our panelists discuss training, access, production capacity, and everything else that is necessary to make RLT more widely available to the patients who need it.Moderator: Ken Herrmann, MD (Universitätsmedizin, Essen, Germany). Panelists: Andrei Iagaru, MD (Stanford University Medical Center, Stanford, California), Leonhard Schaetz (Novartis...
The VISION Trial is the first-in-its-field study to use radiopharmaceuticals that directly target prostate cancer tumors. Hear from one of the lead researchers on this ground-breaking study as he discusses how the trial has opened up a completely new field of study in prostate cancer research and shaped the future of nuclear medicine therapy in combatting the disease. Join us for Episode 4 of JNM Podcast from The Journal of Nuclear Medicine.Moderators: Ken Herrmann, MD (Universitätsmedizin, E...
This month's episode of the JNM Podcast takes the discussion of Pb-212 worldwide! Researchers from the UK, Australia, and North America discuss the logistics of using lead-212 as a radionuclide imaging agent. From availability to production to transportation, Pb-212 presents both great opportunities and great challenges. Moderator Ken Herrmann, MD, leads this intercontinental panel in a discussion about other radionuclides and their pros and cons. He's joined by David Bauer, PhD, from Memoria...
The Journal of Nuclear Medicine presents a new podcast on advances in dementia imaging. Panelists discuss the importance of amyloid and tau PET imaging in dementia diagnosis and treatment, highlighting their roles in clinical trials and future therapies. They emphasize the significance of early detection and the potential for personalized medicine approaches.Panel: • Ken Herrmann, MD, MBA (Universitätsmedizin, Essen, Germany)• Henryk Barthel, MD, PhD (Leipzig University)• Gil Rabinovici,...
The Journal of Nuclear Medicine presents a new podcast on FAPI-directed theranostics for cancer diagnosis and treatment. Join moderator Ken Herrmann (Universitätsmedizin) and panelists Andrew Scott (Austin Health), Katharina Lückerath (Universitätsmedizin) and Shadi Esfahadi (Mass General Hospital) as they delve into the history of FAP, discuss challenges, and predict the pathway to clinical success. #JNuclMed #NuclearMedicine #FAPI #Theranostics